Results demonstrated that the Bcl-xL mRNA expression was dramatically decreased in BM-MNCs derived from adenine-induced CKD rats, whereas ASP treatment attenuated the decrease of Bcl-xL, which was paralleled by EPO therapy (Figure 7D). The gene discussed is BCL2L1; the disease is chronic kidney disease.